PXS-4728A
AssetAlso PXS-4728
Inhibitor of SSAO/VAP-1 (and AOC3) reducing neuroinflammation and microglial activation
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Inflammation
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1REM sleep behavior disorder
Phase 2, Active not recruiting, NCT05904717, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Trials1
- Evidence for its targets1
- Aging relevance1
Every asset’s record: target, stage, trials and the evidence behind it.
See ProUpdated 7 Oct 2026, 1 source